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Abstract 
Moyamoya syndrome is a rare cerebrovascu-
lar  disorder  characterized  by  progressive
occlusion of the supraclinoid internal carotid
artery and proximal portions of the anterior
and middle cerebral arteries resulting in an
extensive network of collateralized blood ves-
sels  and  producing  a  characteristic  angio-
graphic appearance.  Although the pathophysi-
ology is unclear, hematologic disorders have
been associated with development of the moy-
amoya syndrome. A case report is presented. A
29 year-old female with a history of essential
thrombocythemia  developed  progressive
ischemic strokes. Angiography revealed char-
acteristic moyamoya changes and pathologic
examination showed intimal hyperplasia with
scant collagen fibers and myxoid change. This
is  the  first  reported  case  of  moyamoya  syn-
drome  in  an  adult  patient  with  essential
thrombocythemia  demonstrating  histological
findings that suggest a shared pathophysiology
with moyamoya syndrome in sickle cell ane-
mia.  
Introduction
Moyamoya  syndrome,characterized  by  pro-
gressive stenosis resulting in occlusion of the
intracranial circulation and extensive collater-
alization,  produces  a  characteristic  angio-
graphic puff of smoke appearance.1 The supra-
clinoid  internal  carotid  artery  is  primarily
affected  and  the  disease  may  manifest  with
ischemic stroke, transient ischemic attack, or
intracerebral hemorrhage.2
Essential thrombocythemia (ET) is a myelo-
proliferative syndrome defined by overproduc-
tion of platelets with predisposition to vascular
occlusive  events  as  a  result  of  intravascular
stasis and/or qualitative platelet dysfunction.3
ET has been associated with large and small
vessel ischemic stroke,4 as well as micro-ves-
sel vascular occlusive events.5
We report a patient with essential thrombo-
cythemia  who  developed  multiple  ischemic
infarcts due to moyamoya syndrome. To our
knowledge,  the  association  between  ET  and
moyamoya syndrome in an adult has not been
previously reported. 
Case Report
A 29 year-old woman presented with several
brief  attacks  of  dysarthria,  aphasia,  staring,
and loss of consciousness. Essential thrombo-
cythemia was diagnosed two years earlier and
she  was  poorly  compliant  with  hydroxyurea.
Chronic inflammatory demyelinating polyneu-
ropathy  (CIDP)  diagnosed  one  year  prior
resulted in bilateral foot drop. She had diet-
controlled  diabetes,  hypertension,  migraine
headaches, and childhood asthma. She did not
use tobacco or illicit drugs and rarely drank
alcohol.  She presented bradyphrenic and abu-
lic, followed simple commands only, but was
alert. There was distal lower extremity weak-
ness  with  decreased  sensation  and  reflexes
attributed  to  CIDP.  Serum  studies  showed
thrombocytosis  (1,080  K/uL).  Magnetic  reso-
nance imaging (MRI) and angiography (MRA)
revealed bilateral middle cerebral artery nar-
rowing  and  acute  infarcts  (Figure  1A).
Cerebrospinal  fluid  protein  was  elevated 
(114  mg/dL),  consistent  with  CIDP,  but  was
otherwise  unremarkable  including
angiotensin converting enzyme and negative
viral studies (herpes simplex virus and varicel-
la  zoster  virus  polymerase  chain  reaction
tests).  Aspirin (325 mg daily) was initiated on
admission, and due to recurrent strokes clopi-
dogrel (75 mg daily) was added and a three-day
trial  of  methylprednisolone  (1  gram  intra-
venously daily) was implemented on day six for
possible  vasculitis.  Angiography  revealed
severe  stenosis  at  bilateral  distal  internal
carotid arteries (ICA), proximal middle cere-
bral  arteries  (MCA),  and  anterior  cerebral
arteries (ACA) (Figure 1C), meeting Suzuki
criteria for stage 1 moyamoya changes.1
During hospitalization she developed multi-
ple new ischemic infarcts which were thought
to be due to flow failure. Repeat angiography
was  performed  twice  and  cyclophosphamide
therapy was initiated due to persistent throm-
bocytosis (500-600 K/uL). Given the multiple
ischemic infarcts due to hemodynamic failure
and despite multiple endovascular attempts to
ameliorate  flow,  revascularization  surgery
with encephaloduroarteriosynangiosis (EDAS)
was performed on day nineteen.  She remained
poorly  responsive  and  MRI  on  hospital  day
twenty-seven revealed marked progression of
bilateral MCA infarcts (Figure 1B). She died on
hospital day forty-eight due to pulseless elec-
trical activity cardiac arrest. 
Serum studies for human immunodeficien-
cy  virus,  erythrocyte  sedimentation  rate,
hemoglobin electrophoresis, antinuclear anti-
body,  rheumatoid  factor,  complement  assay,
antinuclear cytoplasmic antibody, and anticar-
diolipin antibodies were unrevealing.  Platelet
count peaked at 1099 K/uL during the hospital
course. Bone marrow biopsy was negative for
Jak-2  mutation  and  showed  an  increase  in
megakaryocytes with multiple distinct nuclei
and abnormal nuclear shapes consistent with
essential thrombocytosis. No autopsy was per-
formed. However, histological evaluation of the
superficial  temporal  artery  obtained  at  the
time of EDAS showed intimal thickening with
a  narrowed  lumen  (Figure  2).  The  intima
showed prominent myxoid change with inter-
mixed smooth muscle cells and scant collagen
fibers, but there was no inflammation to sug-
gest  vasculitis.  The  segment  of  middle
meningeal  artery,  dura,  and  brain  tissue
obtained at the time of EDAS (not shown) did
not show pathologic abnormalities. There was
no family history of moyamoya syndrome, and
the patient had no stigmata of neurofibromato-
sis or history of radiotherapy.
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We report the first case of moyamoya syn-
drome  in  an  adult  patient  with  essential
thrombocythemia. The only other case report
of moyamoya syndrome in association with ET
is that of Kornblihtt et al. in an adolescent with
ET.6 However, no pathologic tissue was report-
ed from that patient.
The  initial  description  of  moyamoya  syn-
drome characterized six stages of progression:
narrowing of the carotid fork, initiation of the
moyamoya, intensification of the moyamoya,
minimization of the moyamoya, reduction of
the moyamoya, and disappearance of the moy-
amoya.1 Vessel  occlusion  in  moyamoya  syn-
drome  likely  results  from  a  combination  of
hyperplasia of smooth-muscle cells and lumi-
nal thrombosis; however, the underlying mech-
anism of this process is unknown. Moyamoya
syndrome has been associated with a variety of
conditions  and  a  multifactorial  etiology  has
been suggested, including genetic causes and
environmental  factors  such  as  mutations  in
matrix  metalloproteinases  and  radiation.2
Yamashita  et  al.  proposed  that  the  develop-
ment of intimal thickening may be similar to
the  pathogenesis  of  atherosclerosis  and
involve endothelial injury with incorporation
of fibrin and platelet-rich microemboli into the
arterial wall.7 The media is often attenuated
with an irregular elastic lamina.2 Additionally,
increased  platelet-derived  basic  fibroblast
growth factor (bFGF) has been reported in the
cerebrospinal fluid of patients with moyamoya
syndrome and may be responsible for smooth
muscle  proliferation.8 Moyamoya  syndrome
has been reported with several underlying con-
ditions  including  various  hematologic  disor-
ders.2
Moyamoya  changes  have  been  well-
described in patients with sickle cell anemia
(SCA) and have been reported in up to 43% of
pediatric patients with SCA who have strokes.9
An early description of moyamoya syndrome in
SCA patients suggested that occlusion of the
vasa  vasorum  by  sickled  cells  leads  to
ischemia, progressive intimal and medial-wall
proliferation,  and  vessel  occlusion.10 Large-
artery  intimal  hyperplasia  in  SCA  has  also
been thought to develop from endothelial irri-
tation,  intimal  edema,  and  proliferation  at
arterial bifurcations as a response to repeated
sickle  cell  crises.11 Intimal  hyperplasia  has
been reported in SCA patients in both intra-
and extracranial vascular beds.12
In thrombocythemia, a hyperviscosity state
secondary to thrombocytosis, platelet function
abnormalities, abnormal platelet morphology,
abnormal  arachidonic  acid  metabolism,  and
increased neutrophil-platelet aggregation, are
all implicated in the thrombotic state.13 These
changes,  along  with  elevated  levels  of  bFGF,
may contribute to a pro-thrombotic milieu in
ET that predisposes to endothelial injury and
leads to intimal hyperplasia resulting in pro-
gressive occlusion and thrombosis of medium-
sized arteries. As systemic conditions that can
affect all vascular beds, ET and other hemato-
logic  disorders  would  be  expected  to  cause
generalized intimal hyperplasia and thrombo-
sis which would not be restricted to intracra-
nial  vessels.  Our  pathologic  finding  of
extracranial intimal hyperplasia supports this
hypothesis and provides the first evidence of a
shared pathophysiology between ET and SCA-
related moyamoya syndrome.  
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Figure 1. Diffusion-weighted imaging  on admission demonstrates acute infarcts in the
bilateral middle cerebral artery distributions (A), diffusion-weighted imaging on hospi-
tal day 27 shows new infarcts in the bilateral middle cerebral artery distributions (B).
Cerebral angiography shows severe stenosis (arrows) of the bilateral distal internal carotid
arteries, proximal middle cerebral arteries, and anterior cerebral arteries in both the right
(top) and left (bottom) carotid artery injections (C).
Figure  2.  Histological  evaluation  of  the  superficial  temporal  artery  showing  intimal
hyperplasia due to smooth muscle proliferation, scant collagen fibers, and myxoid change
resulting in a narrowed lumen (H&E (A); Elastic stain (B); Trichrome stain (C); Smooth
muscle actin stain (D)).  Original magnification 100x.References
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